RxDoctor Payments Data

Banshi Rathi, MD

Nephrology · Kingwood, TXNPI 1700035961

Payments from drug & device makers

$8,613in general payments, 2019–2025

Across 411 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Otsuka America Pharmaceutical, Inc.$941
  • Mallinckrodt Hospital Products Inc.$888
  • Amgen$808
  • Aurinia Pharma U.S., Inc.$702
  • ANI Pharmaceuticals, Inc.$691
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$8,50499%
  • Education$1091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,613 in reported general payments places this provider in the 75th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$244,169
Medicare patients
424
Services billed
2,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol107$130,865
VelphoroSucroferric Oxyhydroxide27$46,452
LokelmaSodium Zirconium Cyclosilicate11$13,770
KerendiaFinerenone12$13,671
Sevelamer Carbonate39$7,873
Calcitriol214$4,371
ProsolParenteral Amino Acid 20% No.120$3,166
Bumetanide46$2,687
Calcium Acetate59$2,613
Nifedipine ErNifedipine50$1,660
Potassium Chloride66$1,565
Torsemide33$1,089
Losartan Potassium95$970
Midodrine Hcl19$821
Furosemide98$511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,176$144,636118 claims
Fresenius USA Marketing, Inc.Velphoro$207$46,45227 claims
BayerKerendia$366$13,67112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →